A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Tablet Formulation Under Fed Conditions in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Odalasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 07 Apr 2017 Status changed from recruiting to completed.
- 10 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.
- 10 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.